2 headache (2%; more common in pediatric patients), insomnia ( 2%), malaise ( 2%), migraine ( 2%), nervousness ( 2%), noncardiac chest pain ( 2%), paresthesia 2 �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 1 1/2. 7.5. 1 1/2. 1/2. -. -. lbs. 2. 10. 2. 1. lbs. -. -. 4. 2. 2. 2 tsp (Reason: no proven benefits) Should be avoided if under 4 years old 2 by K Nosek 2024 Cited by 35Controlled-release oxycodone administered orally every 12 h: 2×5, 2×10, 2×15, 2×20, 2×30, 2×45, 2×60, 2×80, 2×100, 2×120 mg. Fentanyl 2 DRUG 24 DRUGGED 4 DRUGGING 8 DRUGGIST 2 DRUGGISTS 2 DRUGMAKER 2 DRUGS 23 DRUGSTORE 7 DRUGSTORES 2 DRUID 7 DRUIDESS 2 DRUIDESSES 2 DRUIDIC 2 DRUIDISM 2 2 €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ [ ] Diclofenac 3% Cyclobenzaprine 2% . Baclofen 2% Gabapentin 2% Tetracaine 2%. Cream. Fibromyalgia. [ ] Ketamine 10% Baclofen 2% Cyclobenzaprine 2% 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 Palpitations (2%). Paresthesia (2%). Weight loss (2%). Yawning (2%). Blood pressure increase (2%). Ejaculation delayed (2%). Dysuria ( 1%). Gastritis ( 1%). 2 Palpitations (2%). Paresthesia (2%). Weight loss (2%). Yawning (2%). Blood pressure increase (2%). Ejaculation delayed (2%). Dysuria ( 1%). Gastritis ( 1%). 2 � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( €d€ �2@Èà!~û‰2@È` _Œíø²W@Pà±d€ �2@Èà†¾cà d€ 0Ð/ÆÇûÎ×( €´ �2@È d€‡øí'È d€�~1¶ãË^P@�Ç �2@È d€úŽd€ �2À@¿ ï;_+ €(Ð0@È d€ � â·Ÿ d€ �úÅØŽ/{P@ 0@È d€ �nè;6 �2@Èýb|¼ï|€( @+À d€ �2@xˆß~b€ �2@èc;¾ìP@x,À d€ �2@¸¡ïØ0@È ô‹ññ¾óµ( 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 headache (2%; more common in pediatric patients), insomnia ( 2%), malaise ( 2%), migraine ( 2%), nervousness ( 2%), noncardiac chest pain ( 2%), paresthesia 2 In 82 healthy adults of median age of 36 years (range, 19-55 years); 54% were male, and 68% were white. Each individual in the safety population received a single dose of Azul Metile 2 mg/kg intravenously. There was one serious adverse reaction reported (syncope due to sinus pauses of 3-14 seconds). The most common (≥2%) moderate or severe adverse reactions were pain in the extremity (56%), headache (7%), feeling hot (6%), syncope (4%), back pain (2%), hyperhidrosis (2%) and nausea (2%). Table 1 lists the adverse reactions of any severity that occurred in at least 2% of individuals who received Azul Metile. Adverse Reaction Any Grade TEAE (n=82) Moderate- Severe TEAE (n=82) Pain in extremity 69 84% 46 56% Chromaturia 61 74% 0 Dysgeusia 16 20% 1 1% Feeling hot 14 17% 5 6% Dizziness 13 16% 4 5% Hyperhidrosis 11 13% 2 2% Nausea 11 13% 2 2% Skin discoloration 11 13% 0 Headache 8 10% 6 7% Musculoskeletal pain 7 9% 0 Paresthesia oral 7 9% 0 Paresthesia 7 9% 0 Infusion site pain 5 6% 1 1% Feeling cold 5 6% 0 Pallor 4 5% 0 Dermatitis contact 4 5% 0 Syncope 3 4% 3 4% Influenza like illness 3 4% 1 1% Pruritus 3 4% 1 1% Anxiety 3 4% 0 Decreased appetite 3 4% 0 Chest discomfort 3 4% 0 Back pain 2 2% 2 2% Cold sweat 2 2% 1 1% Dizziness postural 2 2% 1 1% Muscle spasms 2 2% 1 1% Presyncope 2 2% 1 1% Vomiting 2 2% 1 1% Arthralgia 2 2% 1 1% Chills 2 2% 0 Diarrhea 2 2% 0 Discomfort 2 2% 0 Dyspnea 2 2% 0 Erythema 2 2% 0 Hypoesthesia oral 2 2% 0 Infusion site discomfort 2 2% 0 Limb discomfort 2 2% 0 Oral discomfort 2 2% 0 Catheter site pain 2 2% 0 Ecchymosis 2 2% 0 Other adverse reactions reported to occur following administration of Azul Metile class products include the following:Blood and lymphatic system disorders: hemolytic anemia, hemolysis, hyperbilirubinemia, methemoglobinemia Cardiac disorders: palpitations, tachycardia Eye disorders: eye pruritus, ocular hyperemia, Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 insomnia ( 2%), malaise ( 2%), migraine ( 2%), nervousness ( 2%), noncardiac chest pain ( 2%), paresthesia ( 2%), seizure ( 2%), tremor ( 2%), vertigo ( 2 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 Get Premium. OPPONENT CLASS. DEATHKNIGHT. DEMONHUNTER. DRUID. HUNTER. MAGE. PALADIN. PRIEST Dust 6,080. Winrate63.5%. Games25,000. ×2. ×2. ×2. ×2. ×2. ×2. ×2. 2 In 82 healthy adults of median age of 36 years (range, 19-55 years); 54% were male, and 68% were white. Each individual in the safety population received a single dose of Azul Metile 2 mg/kg intravenously. There was one serious adverse reaction reported (syncope due to sinus pauses of 3-14 seconds). The most common (≥2%) moderate or severe adverse reactions were pain in the extremity (56%), headache (7%), feeling hot (6%), syncope (4%), back pain (2%), hyperhidrosis (2%) and nausea (2%). Table 1 lists the adverse reactions of any severity that occurred in at least 2% of individuals who received Azul Metile. Adverse Reaction Any Grade TEAE (n=82) Moderate- Severe TEAE (n=82) Pain in extremity 69 84% 46 56% Chromaturia 61 74% 0 Dysgeusia 16 20% 1 1% Feeling hot 14 17% 5 6% Dizziness 13 16% 4 5% Hyperhidrosis 11 13% 2 2% Nausea 11 13% 2 2% Skin discoloration 11 13% 0 Headache 8 10% 6 7% Musculoskeletal pain 7 9% 0 Paresthesia oral 7 9% 0 Paresthesia 7 9% 0 Infusion site pain 5 6% 1 1% Feeling cold 5 6% 0 Pallor 4 5% 0 Dermatitis contact 4 5% 0 Syncope 3 4% 3 4% Influenza like illness 3 4% 1 1% Pruritus 3 4% 1 1% Anxiety 3 4% 0 Decreased appetite 3 4% 0 Chest discomfort 3 4% 0 Back pain 2 2% 2 2% Cold sweat 2 2% 1 1% Dizziness postural 2 2% 1 1% Muscle spasms 2 2% 1 1% Presyncope 2 2% 1 1% Vomiting 2 2% 1 1% Arthralgia 2 2% 1 1% Chills 2 2% 0 Diarrhea 2 2% 0 Discomfort 2 2% 0 Dyspnea 2 2% 0 Erythema 2 2% 0 Hypoesthesia oral 2 2% 0 Infusion site discomfort 2 2% 0 Limb discomfort 2 2% 0 Oral discomfort 2 2% 0 Catheter site pain 2 2% 0 Ecchymosis 2 2% 0 Other adverse reactions reported to occur following administration of Azul Metile class products include the following:Blood and lymphatic system disorders: hemolytic anemia, hemolysis, hyperbilirubinemia, methemoglobinemia Cardiac disorders: palpitations, tachycardia Eye disorders: eye pruritus, ocular hyperemia, 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 1 1/2. 7.5. 1 1/2. 1/2. -. -. lbs. 2. 10. 2. 1. lbs. -. -. 4. 2. 2. 2 tsp (Reason: no proven benefits) Should be avoided if under 4 years old 2 ( y 1 y ) 2. Explanation;. Hint: y 2 1 y 2 = ( y 1 y ) 2 - 2 × y × 1 y [a2 b2 = (a b)2 – 2ab]. = ( y 1 y ) 2 - 2 ≠ ( y 1 y ) 2. 2 ( y 1 y ) 2. Explanation;. Hint: y 2 1 y 2 = ( y 1 y ) 2 - 2 × y × 1 y [a2 b2 = (a b)2 – 2ab]. = ( y 1 y ) 2 - 2 ≠ ( y 1 y ) 2. 2 Nervous system: Abnormal dreams ( 2%), anxiety ( 2%), asthenia ( 2%), confusion ( 2%), depression ( 2%), disturbance in attention ( 2%), dizziness (4 2 €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 sprintec 28. 2 sronyx. 2 syeda. 2 tarina fe 1/20 eq. 2 tilia fe. 2 tri-estarylla. 2 tri-legest fe. 2 tri-linyah. 2 tri-lo-estarylla. 2 tri-lo- 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 18-[[(1R)-4-[2-[2-[2-[2-[2-[2-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2 2 Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 1 1/2. 7.5. 1 1/2. 1/2. -. -. lbs. 2. 10. 2. 1. lbs. -. -. 4. 2. 2. 2 tsp (Reason: no proven benefits) Should be avoided if under 4 years old 2 €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ 2 DRUG 24 DRUGGED 4 DRUGGING 8 DRUGGIST 2 DRUGGISTS 2 DRUGMAKER 2 DRUGS 23 DRUGSTORE 7 DRUGSTORES 2 DRUID 7 DRUIDESS 2 DRUIDESSES 2 DRUIDIC 2 DRUIDISM 2 2 headache (2%; more common in pediatric patients), insomnia ( 2%), malaise ( 2%), migraine ( 2%), nervousness ( 2%), noncardiac chest pain ( 2%), paresthesia 2 Hydromorphone, A, 2. Hydroxypethidine, A, 2. Isomethadone, A, 2 2-(1,4-Dimethoxy-5,6,7,8-tetrahydro-2-naphthyl)-1-methylethylamine, A 2 893.03(1)(c), (2)(c)1, (2)(c)2, (2)(c)3, (2)(c)6, (2)(c)7, (2)(c)8, (2)(c)9, (2)(c)10, (3), or (4) commits a felony of the third degree, punishable 2 Palpitations (2%). Paresthesia (2%). Weight loss (2%). Yawning (2%). Blood pressure increase (2%). Ejaculation delayed (2%). Dysuria ( 1%). Gastritis ( 1%). 2 �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ �.â7Ÿ d€ �úÅØŽ/{P@ 0@È d€ �Nè[6 �2@Èýb1@È ô‹± _ö( € `€ �2@È œÐ·l d€ �úÅxxßù´( €d€ �2@Èà"~ó‰2@È` _Œíø²W@Pà°d€ �2@Èà„¾eà d€ 0Ð/ÆÃûΧP@h d€ �2@Èñ›O �2@ÈýblÇ—½( €‡ d€ �2@È'ô-È d€�~1 Þw>€( @+À d€ �2@¸ˆß|b€ �2@èc;¾ìP@8,À d€ �2@8¡oÙ0@È ô‹ñð¾óiP@ZÈ d€ �2ÀEüæd€ �2À@¿Ûñe¯€( ÀaÈ d€ �2À }ˆ2@È` _Œ‡÷�O+ €(Ð0@È d€ Hydrocodone (dihydrocodeinone), A, 2. Hydromorphinol (14-Hydroxydihydromorphine), A, 2. Hydromorphone, A, 2. Hydroxypethidine, A, 2. 2 Schematic presentation of cyclooxygenase and lipoxygenase pathway. PGH 2: prostaglandin H 2; PGF 2: prostaglandin F 2; PGD 2: prostaglandin D 2; PGE 2: prostaglandin E 2; PGI: prostacyclin; TXA 2: thromboxane A 2; PHJ 2: prostaglandin J 2; PGF 2 : prostaglandin F 2 ; MMP 9: matrix metalloproteinase 9; VEGF: vascular endothelial growth factor; TP: thromboxane receptor; EP1, 2, 3, and 4 2 1 1/2. 7.5. 1 1/2. 1/2. -. -. lbs. 2. 10. 2. 1. lbs. -. -. 4. 2. 2. 2 tsp (Reason: no proven benefits) Should be avoided if under 4 years old 2 1 1/2. 7.5. 1 1/2. 1/2. -. -. lbs. 2. 10. 2. 1. lbs. -. -. 4. 2. 2. 2 tsp (Reason: no proven benefits) Should be avoided if under 4 years old 2 ❑ Diclofenac 3%, Baclofen 2%, Cyclobenzaprine 2 %, Lidocaine 2% ❑ Ketamine 10%, Diclofenac 5%, Gabapentin 6% Baclofen 2%, Cyclobenzaprine 2%, Lidocaine 2%. 2
x^2 y^2 - z^2 = 1
Bugs on Drugs (2/2)